Neelakshi Patel, MD
Rheumatology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
Offices
2 locations · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Patel’s office at (408) 340-5700 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A84629 · Current
Licensed to practise in California · since 2003 · expires 2027-08-31 · Jabalpur University Medical College Aka Rani Durgavati Vishwavidyalaya.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$548,810
Medicare paid this office $548,810 for 428 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 94 | $183,450 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $144,339 | None |
| Return visit (30+ min) | 344 | $77,165 | $116 |
| Long return visit (40+ min) | 110 | $29,401 | $168 |
| Short return visit (20+ min) | 120 | $11,806 | $81 |
See all 16 services
| Injection, denosumab, 1 mg | 94 | $183,450 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $144,339 | None |
| Return visit (30+ min) | 344 | $77,165 | $116 |
| Long return visit (40+ min) | 110 | $29,401 | $168 |
| Short return visit (20+ min) | 120 | $11,806 | $81 |
| Injection of drug or substance under skin or into muscle | 118 | $6,272 | $14 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 275 | $6,170 | $15 |
| New patient visit (60+ min) | 30 | $5,501 | $183 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 24 | $2,830 | $98 |
| Influenza vaccine split virus, preservative free | 26 | $2,127 | $82 |
| Aspiration and/or injection of fluid from large joint | 23 | $1,857 | $62 |
| New patient visit (45+ min) | 14 | $1,832 | $131 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,255 | $78 |
| Administration of influenza virus vaccine | 28 | $1,070 | $38 |
| Aspiration and/or injection of fluid from small joint | 11 | $759 | $51 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 60 | $196 | None |
Who their Medicare patients are
428 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 21% · Women 80% · Also on Medicaid 6% · Health risk score 1.31. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 74% · Coronary heart disease 29% · Diabetes 25% · Chronic kidney disease 20% · Atrial fibrillation 18% · Depression 17% · Cancer 15% · Heart failure 14% · COPD 13% · Stroke 8% · Dementia 7%.
The office billed $2,512,116, Medicare allowed $698,745 and paid $548,810; for 59,796 services of 34 kinds; $400,314 of it was for drugs given in the office and $148,497 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 428 | 59,796 | 77 | 1.31 | $2,512,116 | $548,810 |
| 2023 | 416 | 57,070 | 77 | 1.29 | $2,696,985 | $597,646 |
| 2022 | 439 | 116,782 | 77 | 1.30 | $5,105,516 | $1,136,583 |
| 2021 | 463 | 94,873 | 76 | 1.29 | $4,801,203 | $1,082,734 |
| 2020 | 460 | 66,186 | 76 | 1.29 | $3,482,887 | $803,633 |
| 2019 | 479 | 119,420 | 77 | 1.41 | $5,910,595 | $1,430,958 |
| 2018 | 453 | 106,696 | 77 | 1.41 | $4,804,419 | $1,237,440 |
| 2017 | 479 | 139,295 | 76 | 1.47 | $5,692,282 | $1,375,505 |
| 2016 | 548 | 99,139 | 76 | 1.41 | $3,437,631 | $940,667 |
| 2015 | 392 | 43,714 | 75 | 1.33 | $1,218,400 | $406,521 |
| 2014 | 321 | 27,578 | 75 | 1.26 | $644,845 | $261,694 |
| 2013 | 299 | 20,296 | 75 | 1.21 | $669,800 | $285,205 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Injection, denosumab, 1 mg | 76 | $128,549 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $107,690 | None |
| Return visit (30+ min) | 325 | $76,112 | $115 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $73,848 | None |
| Injection, tocilizumab, 1 mg | 11 | $57,582 | None |
| Long return visit (40+ min) | 108 | $32,490 | $166 |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $28,493 | None |
| Short return visit (20+ min) | 96 | $9,796 | $81 |
| New patient visit (60+ min) | 40 | $7,918 | $198 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 44 | $5,744 | $65 |
| Injection of drug or substance under skin or into muscle | 113 | $4,385 | $14 |
| Influenza vaccine split virus, preservative free | 36 | $2,589 | $72 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 21 | $2,108 | $96 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $1,739 | $87 |
| Administration of influenza virus vaccine | 36 | $1,331 | $37 |
| New patient visit (45+ min) | 11 | $1,291 | $117 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,095 | $61 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 61 | $200 | None |
| Injection, methylprednisolone acetate, 40 mg | 11 | $183 | None |
2022: 20 services
| Injection, tocilizumab, 1 mg | 18 | $269,806 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15 | $242,609 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $125,936 | None |
| Injection, denosumab, 1 mg | 77 | $119,478 | None |
| Injection, golimumab, 1 mg, for intravenous use | 13 | $94,094 | None |
| Return visit (30+ min) | 357 | $82,956 | $114 |
| Long return visit (40+ min) | 132 | $36,355 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 72 | $22,165 | $72 |
| New patient visit (60+ min) | 39 | $7,715 | $198 |
| Short return visit (20+ min) | 53 | $5,464 | $88 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | $4,114 | $111 |
| Injection of drug or substance under skin or into muscle | 98 | $4,081 | $14 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 25 | $2,979 | $99 |
| Aspiration and/or injection of fluid from large joint | 20 | $1,783 | $69 |
| Influenza vaccine split virus, preservative free | 26 | $1,782 | $69 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,777 | $77 |
| Administration of influenza virus vaccine | 27 | $1,005 | $37 |
| Aspiration and/or injection of fluid from small joint | 12 | $931 | $52 |
| Injection, zoledronic acid, 1 mg | 26 | $729 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 69 | $288 | None |
2021: 22 services
| Injection, tocilizumab, 1 mg | 21 | $218,902 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $189,931 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 23 | $124,298 | None |
| Injection, denosumab, 1 mg | 76 | $99,418 | None |
| Return visit (30+ min) | 355 | $98,435 | $124 |
| Injection, golimumab, 1 mg, for intravenous use | 18 | $96,705 | None |
| Long return visit (40+ min) | 88 | $21,532 | $184 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 80 | $19,274 | $78 |
| Telephone medical discussion with physician, 21-30 minutes | 83 | $14,491 | $117 |
| New patient visit (60+ min) | 26 | $5,875 | $226 |
| Short return visit (20+ min) | 62 | $5,308 | $76 |
| Telephone medical discussion with physician, 11-20 minutes | 43 | $3,992 | $75 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 21 | $3,377 | $94 |
| Injection of drug or substance under skin or into muscle | 117 | $3,356 | $14 |
| Influenza vaccine split virus, preservative free | 37 | $2,415 | $65 |
| New patient visit (45+ min) | 14 | $2,062 | $147 |
| Aspiration and/or injection of fluid from large joint | 17 | $1,305 | $69 |
| Injection, zoledronic acid, 1 mg | 26 | $1,062 | None |
| Administration of influenza virus vaccine | 40 | $877 | $22 |
| Injection into tendon or ligament | 13 | $863 | $48 |
| Aspiration and/or injection of fluid from small joint | 14 | $771 | $45 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 66 | $344 | None |
2020: 23 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $133,193 | None |
| Injection, tocilizumab, 1 mg | 13 | $119,315 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $102,718 | None |
| Injection, golimumab, 1 mg, for intravenous use | 18 | $98,703 | None |
| Injection, denosumab, 1 mg | 72 | $95,272 | None |
| Return visit (30+ min) | 322 | $63,357 | $97 |
| Telephone medical discussion with physician, 21-30 minutes | 106 | $15,654 | $106 |
| Telephone medical discussion with physician, 11-20 minutes | 145 | $15,223 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 76 | $13,324 | $69 |
| Short return visit (20+ min) | 114 | $10,095 | $67 |
| Long return visit (40+ min) | 58 | $9,264 | $120 |
| New patient visit (60+ min) | 27 | $5,354 | $198 |
| New patient visit (45+ min) | 28 | $4,182 | $149 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 26 | $4,008 | $91 |
| Injection of drug or substance under skin or into muscle | 107 | $2,884 | $13 |
| Aspiration and/or injection of fluid from large joint | 19 | $1,253 | $60 |
| Influenza vaccine split virus, preservative free | 18 | $1,079 | $60 |
| Injection, zoledronic acid, 1 mg | 24 | $1,021 | None |
| Injection into tendon or ligament | 13 | $1,019 | $49 |
| Aspiration and/or injection of fluid from small joint | 14 | $744 | $41 |
| Administration of influenza virus vaccine | 22 | $459 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 66 | $372 | None |
| Injection, methylprednisolone acetate, 40 mg | 11 | $159 | None |
2019: 23 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $288,189 | None |
| Injection, tocilizumab, 1 mg | 14 | $220,714 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $189,877 | None |
| Injection, golimumab, 1 mg, for intravenous use | 19 | $170,499 | None |
| Injection, denosumab, 1 mg | 86 | $121,276 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 13 | $90,513 | None |
| Return visit (30+ min) | 384 | $89,691 | $97 |
| Long return visit (40+ min) | 126 | $29,242 | $135 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 77 | $23,595 | $72 |
| Short return visit (20+ min) | 91 | $8,037 | $65 |
| New patient visit (60+ min) | 30 | $5,811 | $194 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 42 | $5,740 | $90 |
| Injection of drug or substance under skin or into muscle | 129 | $5,315 | $16 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $4,760 | $140 |
| New patient visit (45+ min) | 26 | $3,899 | $150 |
| Influenza vaccine split virus, preservative free | 19 | $1,043 | $55 |
| Administration of chemotherapy into vein, each additional hour | 12 | $1,039 | $31 |
| Injection, zoledronic acid, 1 mg | 22 | $924 | None |
| Aspiration and/or injection of fluid from small joint | 14 | $881 | $44 |
| Short return visit | 12 | $536 | $45 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 75 | $529 | None |
| Administration of influenza virus vaccine | 20 | $410 | $21 |
| Injection, methylprednisolone acetate, 40 mg | 13 | $149 | None |
2018: 22 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $239,908 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $186,538 | None |
| Injection, tocilizumab, 1 mg | 12 | $177,819 | None |
| Injection, denosumab, 1 mg | 98 | $130,351 | None |
| Return visit (30+ min) | 383 | $89,643 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 59 | $20,544 | $74 |
| Long return visit (40+ min) | 81 | $17,543 | $135 |
| Short return visit (20+ min) | 144 | $11,138 | $64 |
| Injection of drug or substance under skin or into muscle | 141 | $6,811 | $20 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 40 | $5,538 | $87 |
| New patient visit (45+ min) | 25 | $3,828 | $153 |
| New patient visit (60+ min) | 13 | $2,326 | $179 |
| Aspiration and/or injection of fluid from small joint | 19 | $908 | $41 |
| Aspiration and/or injection of fluid from large joint | 14 | $790 | $44 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $772 | $21 |
| Influenza vaccine split virus, preservative free | 14 | $732 | $52 |
| Injection, zoledronic acid, 1 mg | 13 | $682 | None |
| Short return visit | 13 | $554 | $43 |
| X-ray of chest, 2 views | 30 | $549 | $18 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 77 | $531 | None |
| Administration of influenza virus vaccine | 15 | $386 | $26 |
| Injection, methylprednisolone acetate, 40 mg | 17 | $199 | None |
2017: 27 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $240,802 | None |
| Injection, tocilizumab, 1 mg | 12 | $237,034 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $227,508 | None |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $147,088 | None |
| Return visit (30+ min) | 420 | $106,926 | $97 |
| Injection, denosumab, 1 mg | 85 | $102,870 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 66 | $23,704 | $69 |
| Long return visit (40+ min) | 112 | $21,411 | $135 |
| Short return visit (20+ min) | 139 | $11,498 | $62 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 62 | $9,359 | $84 |
| Injection of drug or substance under skin or into muscle | 122 | $9,144 | $25 |
| New patient visit (60+ min) | 34 | $6,393 | $188 |
| New patient visit (45+ min) | 33 | $4,755 | $144 |
| Mri scan of leg joint without contrast | 11 | $1,980 | $180 |
| Influenza vaccine split virus, preservative free | 30 | $1,490 | $48 |
| Injection, zoledronic acid, 1 mg | 27 | $1,351 | None |
| Administration of influenza virus vaccine | 40 | $1,324 | $32 |
| Aspiration and/or injection of fluid from small joint | 18 | $1,257 | $41 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $1,112 | $18 |
| Aspiration and/or injection of fluid from large joint | 18 | $1,107 | $53 |
| X-ray of chest, 2 views, front and side | 58 | $998 | $17 |
| X-ray of hand, minimum of 3 views | 24 | $932 | $23 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 101 | $846 | None |
| X-ray of knee, 3 views | 21 | $752 | $24 |
| Short return visit | 14 | $632 | $42 |
| X-ray of wrist, minimum of 3 views | 14 | $545 | $29 |
| Injection, methylprednisolone acetate, 20 mg | 13 | $187 | None |
2016: 31 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $187,935 | None |
| Injection, tocilizumab, 1 mg | 16 | $176,177 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $123,941 | None |
| Return visit (30+ min) | 395 | $91,698 | $94 |
| Injection, denosumab, 1 mg | 67 | $66,676 | None |
| New patient visit (45+ min) | 135 | $19,320 | $143 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $16,765 | $66 |
| Short return visit (20+ min) | 156 | $15,063 | $63 |
| New patient visit (60+ min) | 68 | $12,160 | $179 |
| Long return visit (40+ min) | 55 | $7,908 | $126 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 41 | $6,789 | $67 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 38 | $5,808 | $78 |
| Injection of drug or substance under skin or into muscle | 97 | $4,246 | $25 |
| X-ray of hand, minimum of 3 views | 50 | $2,627 | $29 |
| New patient visit (30+ min) | 21 | $2,072 | $99 |
| Injection, zoledronic acid, 1 mg | 23 | $1,654 | None |
| X-ray of knee, 3 views | 27 | $1,270 | $31 |
| X-ray of chest, 2 views, front and side | 48 | $1,075 | $22 |
| X-ray of foot, minimum of 3 views | 19 | $875 | $27 |
| X-ray of lower and sacral spine, minimum of 4 views | 18 | $832 | $46 |
| X-ray of hip, 2-3 views | 19 | $788 | $36 |
| Injection into tendon or ligament | 12 | $759 | $54 |
| X-ray of upper spine, 6 or more views | 15 | $747 | $50 |
| Administration of influenza virus vaccine | 22 | $697 | $32 |
| X-ray of wrist, minimum of 3 views | 12 | $695 | $33 |
| X-ray of shoulder, minimum of 2 views | 18 | $593 | $24 |
| Aspiration and/or injection of fluid from small joint | 11 | $523 | $35 |
| Influenza vaccine split virus, preservative free | 12 | $502 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 76 | $454 | None |
| Injection, methylprednisolone acetate, 40 mg | 24 | $211 | None |
| Infusion, normal saline solution, 250 cc | 34 | $47 | None |
2015: 24 services
| Return visit (30+ min) | 293 | $80,626 | $99 |
| Injection, denosumab, 1 mg | 32 | $27,622 | None |
| Short return visit (20+ min) | 146 | $15,546 | $65 |
| New patient visit (45+ min) | 94 | $14,059 | $150 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 43 | $10,552 | $76 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 29 | $8,300 | $72 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 41 | $6,105 | $79 |
| X-ray of hand, minimum of 3 views | 56 | $2,833 | $30 |
| New patient visit (60+ min) | 12 | $2,235 | $186 |
| New patient visit (30+ min) | 22 | $2,128 | $97 |
| Injection, zoledronic acid, 1 mg | 14 | $1,855 | None |
| Long return visit (40+ min) | 12 | $1,627 | $136 |
| X-ray of chest, 2 views, front and side | 50 | $1,434 | $27 |
| X-ray of knee, 3 views | 27 | $1,399 | $33 |
| Aspiration and/or injection of fluid from large joint | 20 | $1,348 | $50 |
| X-ray of foot, minimum of 3 views | 20 | $948 | $29 |
| X-ray of wrist, minimum of 3 views | 19 | $933 | $33 |
| Administration of influenza virus vaccine | 27 | $858 | $32 |
| X-ray of lower and sacral spine, minimum of 4 views | 17 | $798 | $47 |
| X-ray of shoulder, minimum of 2 views | 15 | $515 | $29 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 64 | $434 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 25 | $295 | $12 |
| Injection, methylprednisolone acetate, 40 mg | 21 | $147 | None |
| Infusion, normal saline solution, 250 cc | 32 | $44 | None |
2014: 24 services
| Return visit (30+ min) | 264 | $75,665 | $97 |
| Injection, denosumab, 1 mg | 23 | $22,917 | None |
| Insertion of needle or tube into artery of arm or leg | 15 | $16,190 | $274 |
| New patient visit (45+ min) | 60 | $8,656 | $144 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $7,781 | $67 |
| Short return visit (20+ min) | 79 | $6,747 | $67 |
| New patient visit (30+ min) | 31 | $3,109 | $100 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $3,062 | $58 |
| Ultrasonic guidance for needle placement | 32 | $2,839 | $71 |
| Injection of drug or substance under skin or into muscle | 47 | $1,999 | $24 |
| Injection into tendon or ligament | 28 | $1,862 | $53 |
| X-ray of hand, minimum of 3 views | 36 | $1,623 | $26 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,196 | $54 |
| X-ray of lower and sacral spine, minimum of 4 views | 20 | $711 | $36 |
| X-ray of knee, 3 views | 16 | $700 | $29 |
| X-ray of chest, 2 views, front and side | 31 | $677 | $21 |
| X-ray of ribs of one side of body, minimum of 2 views | 20 | $628 | $29 |
| X-ray of wrist, minimum of 3 views | 11 | $559 | $31 |
| Administration of influenza virus vaccine | 17 | $529 | $31 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 49 | $274 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 17 | $256 | $15 |
| Injection, triamcinolone hexacetonide, per 5 mg | 47 | $247 | None |
| Injection, methylprednisolone acetate, 40 mg | 17 | $91 | None |
| Infusion, normal saline solution, 250 cc | 15 | $18 | None |
2013: 20 services
| Return visit (30+ min) | 261 | $77,712 | $95 |
| Insertion of needle or tube into artery of arm or leg | 27 | $23,300 | $284 |
| New patient visit (45+ min) | 82 | $12,173 | $148 |
| Injection, denosumab, 1 mg | 11 | $11,385 | None |
| Ultrasonic guidance for needle placement | 22 | $6,588 | $213 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 25 | $3,742 | $73 |
| Insertion of artery tube for prolonged infusion | 12 | $3,413 | $114 |
| Aspiration and/or injection of fluid from large joint | 32 | $2,713 | $53 |
| Injection of drug or substance under skin or into muscle | 39 | $2,665 | $25 |
| Injection into tendon or ligament | 24 | $1,587 | $45 |
| X-ray of hand, minimum of 3 views | 35 | $1,577 | $26 |
| Administration of influenza virus vaccine | 46 | $1,478 | $32 |
| Aspiration and/or injection of fluid from medium joint | 17 | $1,437 | $57 |
| X-ray of knee, 3 views | 20 | $826 | $31 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 46 | $674 | $15 |
| X-ray of chest, 2 views, front and side | 23 | $510 | $21 |
| Injection, triamcinolone hexacetonide, per 5 mg | 59 | $466 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 60 | $431 | None |
| Injection, methylprednisolone acetate, 40 mg | 20 | $75 | None |
| Infusion, normal saline solution, 250 cc | 23 | $14 | None |
Drugs they prescribed that Part D paid
$1,682,551
Pharmacies billed $1,682,551 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (95 of 1,854) in 2024. Above the middle of the specialty; the typical rheumatology clinician is at 3%.
1,495 generic and 342 brand-name prescriptions · $1,682,551 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Orencia Clickject | 33 | $195,727 | $5,931 |
| Tymlos | 54 | $146,202 | $2,707 |
| Humira(Cf) | 18 | $136,065 | $7,559 |
| Cosentyx Sensoready | 15 | $125,388 | $8,359 |
| Enbrel | 16 | $115,147 | $7,197 |
See all 30 drugs
| Orencia Clickject | 33 | $195,727 | $5,931 |
| Tymlos | 54 | $146,202 | $2,707 |
| Humira(Cf) | 18 | $136,065 | $7,559 |
| Cosentyx Sensoready | 15 | $125,388 | $8,359 |
| Enbrel | 16 | $115,147 | $7,197 |
| Humira | 15 | $101,855 | $6,790 |
| Cimzia (2 Pack) | 11 | $61,594 | $5,599 |
| Kevzara | 13 | $61,034 | $4,695 |
| Teriparatide | 16 | $32,485 | $2,030 |
| Hydroxychloroquine Sulfate | 242 | $11,149 | $46 |
| Methotrexate | 136 | $5,670 | $42 |
| Celecoxib | 66 | $4,005 | $61 |
| Leflunomide | 53 | $3,633 | $69 |
| Sulfasalazine | 103 | $2,743 | $27 |
| Gabapentin | 153 | $2,621 | $17 |
| Mycophenolate Mofetil | 12 | $2,237 | $186 |
| Prednisone | 186 | $1,942 | $10 |
| Pregabalin | 44 | $1,471 | $33 |
| Ibandronate | 30 | $1,339 | $45 |
| Allopurinol | 58 | $814 | $14 |
| Duloxetine | 33 | $784 | $24 |
| Hydrocodone-Acetaminophen | 32 | $775 | $24 |
| Folic Acid | 41 | $737 | $18 |
| Tramadol | 50 | $631 | $13 |
| Etodolac | 12 | $582 | $49 |
| Alendronate | 53 | $515 | $10 |
| Nabumetone | 38 | $467 | $12 |
| Meloxicam | 39 | $285 | $7 |
| Cyclobenzaprine | 20 | $236 | $12 |
| Methotrexate | 21 | $200 | $10 |
Year by year
| 2024 | 1,854 | 374 | 5% (95) | 18% | $1,682,551 |
| 2023 | 1,704 | 322 | 5% (80) | 13% | $1,207,031 |
| 2022 | 1,780 | 315 | 6% (106) | 11% | $867,823 |
| 2021 | 1,807 | 300 | 7% (131) | None | $814,463 |
| 2020 | 1,986 | 276 | 8% (153) | 15% | $677,464 |
| 2019 | 1,940 | 288 | 9% (178) | 17% | $670,805 |
| 2018 | 1,689 | 256 | 8% (127) | 20% | $664,894 |
| 2017 | 2,240 | 255 | 6% (141) | 20% | $895,466 |
| 2016 | 1,888 | 246 | 7% (123) | None | $358,151 |
| 2015 | 1,479 | 180 | 6% (89) | 21% | $179,817 |
| 2014 | 1,332 | 177 | 5% (69) | None | $162,993 |
| 2013 | 1,321 | 142 | 5% (69) | 19% | $124,153 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Cosentyx Sensoready (2 Pens) | 13 | $185,804 | $14,293 |
| Humira(Cf) | 19 | $146,824 | $7,728 |
| Cosentyx Sensoready | 14 | $105,712 | $7,551 |
| Enbrel | 12 | $81,214 | $6,768 |
| Forteo | 18 | $76,714 | $4,262 |
| Kevzara | 11 | $45,066 | $4,097 |
| Tymlos | 16 | $44,500 | $2,781 |
| Hydroxychloroquine Sulfate | 233 | $13,111 | $56 |
| Celecoxib | 78 | $6,137 | $79 |
| Leflunomide | 56 | $5,896 | $105 |
| Methotrexate | 126 | $5,668 | $45 |
| Cevimeline | 13 | $2,946 | $227 |
| Mycophenolate Mofetil | 16 | $2,799 | $175 |
| Prednisone | 184 | $2,645 | $14 |
| Gabapentin | 113 | $2,343 | $21 |
| Pregabalin | 28 | $2,342 | $84 |
| Duloxetine | 38 | $2,325 | $61 |
| Sulfasalazine | 78 | $2,290 | $29 |
| Colchicine | 16 | $1,930 | $121 |
| Ibandronate | 24 | $1,443 | $60 |
| Allopurinol | 56 | $959 | $17 |
| Alendronate | 60 | $772 | $13 |
| Hydrocodone-Acetaminophen | 29 | $604 | $21 |
| Nabumetone | 36 | $485 | $13 |
| Leucovorin | 15 | $461 | $31 |
| Tramadol | 44 | $409 | $9 |
| Nifedipine Er | 13 | $367 | $28 |
| Meloxicam | 37 | $283 | $8 |
| Folic Acid | 58 | $179 | $3 |
| Cyclobenzaprine | 12 | $158 | $13 |
| Methotrexate | 12 | $115 | $10 |
| Zolpidem | 14 | $43 | $3 |
2022: 32 drugs
| Cosentyx Pen (2 Pens) | 14 | $152,388 | $10,885 |
| Humira(Cf) | 13 | $81,409 | $6,262 |
| Forteo | 19 | $79,523 | $4,185 |
| Hydroxychloroquine Sulfate | 237 | $17,010 | $72 |
| Rasuvo | 13 | $11,563 | $889 |
| Leflunomide | 84 | $11,056 | $132 |
| Methotrexate | 193 | $8,197 | $42 |
| Celecoxib | 68 | $3,336 | $49 |
| Prednisone | 210 | $2,938 | $14 |
| Colchicine | 15 | $2,908 | $194 |
| Gabapentin | 101 | $2,771 | $27 |
| Sulfasalazine | 52 | $2,550 | $49 |
| Cevimeline | 11 | $2,520 | $229 |
| Pregabalin | 32 | $1,992 | $62 |
| Mycophenolate Mofetil | 11 | $1,487 | $135 |
| Diclofenac | 13 | $1,304 | $100 |
| Ibandronate | 23 | $1,206 | $52 |
| Duloxetine | 42 | $1,004 | $24 |
| Allopurinol | 54 | $933 | $17 |
| Hydrocodone-Acetaminophen | 44 | $845 | $19 |
| Leucovorin | 16 | $577 | $36 |
| Nabumetone | 25 | $559 | $22 |
| Alendronate | 61 | $503 | $8 |
| Cyclobenzaprine | 15 | $489 | $33 |
| Tramadol | 44 | $387 | $9 |
| Folic Acid | 59 | $346 | $6 |
| Methotrexate | 22 | $295 | $13 |
| Meloxicam | 52 | $280 | $5 |
| Omeprazole | 15 | $276 | $18 |
| Acetaminophen-Codeine | 12 | $275 | $23 |
| Trazodone | 11 | $199 | $18 |
| Zolpidem | 11 | $79 | $7 |
2021: 26 drugs
| Forteo | 23 | $113,134 | $4,919 |
| Cosentyx | 14 | $88,821 | $6,344 |
| Hydroxychloroquine Sulfate | 240 | $17,692 | $74 |
| Methotrexate | 194 | $9,993 | $52 |
| Leflunomide | 65 | $7,810 | $120 |
| Celecoxib | 51 | $3,845 | $75 |
| Sulfasalazine | 76 | $3,328 | $44 |
| Prednisone | 209 | $3,312 | $16 |
| Gabapentin | 124 | $3,134 | $25 |
| Cevimeline | 14 | $2,107 | $150 |
| Colchicine | 17 | $1,579 | $93 |
| Pregabalin | 19 | $1,421 | $75 |
| Duloxetine | 41 | $1,275 | $31 |
| Hydrocodone-Acetaminophen | 52 | $1,136 | $22 |
| Leucovorin | 21 | $747 | $36 |
| Tramadol | 54 | $745 | $14 |
| Allopurinol | 47 | $728 | $15 |
| Methotrexate | 47 | $723 | $15 |
| Nabumetone | 29 | $681 | $23 |
| Alendronate | 45 | $679 | $15 |
| Nifedipine Er | 13 | $620 | $48 |
| Acetaminophen-Codeine | 21 | $488 | $23 |
| Meloxicam | 56 | $328 | $6 |
| Omeprazole | 16 | $306 | $19 |
| Folic Acid | 37 | $192 | $5 |
| Zolpidem | 12 | $86 | $7 |
2020: 34 drugs
| Humira | 16 | $143,719 | $8,982 |
| Forteo | 21 | $106,375 | $5,065 |
| Cosentyx | 12 | $71,152 | $5,929 |
| Xeljanz | 11 | $54,603 | $4,964 |
| Olumiant | 12 | $26,213 | $2,184 |
| Hydroxychloroquine Sulfate | 293 | $23,828 | $81 |
| Prolia | 11 | $14,434 | $1,312 |
| Rasuvo | 12 | $10,854 | $905 |
| Leflunomide | 85 | $9,755 | $115 |
| Methotrexate | 166 | $7,476 | $45 |
| Cevimeline | 17 | $4,653 | $274 |
| Celecoxib | 62 | $4,312 | $70 |
| Colchicine | 25 | $3,328 | $133 |
| Sulfasalazine | 65 | $3,040 | $47 |
| Prednisone | 252 | $3,020 | $12 |
| Mycophenolate Mofetil | 14 | $2,840 | $203 |
| Gabapentin | 155 | $2,044 | $13 |
| Hydrocodone-Acetaminophen | 65 | $1,573 | $24 |
| Pregabalin | 35 | $1,415 | $40 |
| Duloxetine | 40 | $1,075 | $27 |
| Diclofenac | 18 | $800 | $44 |
| Leucovorin | 23 | $772 | $34 |
| Tramadol | 63 | $699 | $11 |
| Methotrexate | 51 | $633 | $12 |
| Nabumetone | 37 | $569 | $15 |
| Alendronate | 38 | $505 | $13 |
| Eszopiclone | 12 | $496 | $41 |
| Omeprazole | 32 | $495 | $15 |
| Nifedipine Er | 20 | $491 | $25 |
| Allopurinol | 30 | $454 | $15 |
| Acetaminophen-Codeine | 24 | $228 | $9 |
| Meloxicam | 46 | $214 | $5 |
| Zolpidem | 16 | $124 | $8 |
| Insulin | 15 | $55 | $4 |
2019: 34 drugs
| Cosentyx | 15 | $86,958 | $5,797 |
| Xeljanz | 17 | $76,275 | $4,487 |
| Otezla | 19 | $65,419 | $3,443 |
| Enbrel Sureclick | 12 | $61,909 | $5,159 |
| Humira | 11 | $57,283 | $5,208 |
| Hydroxychloroquine Sulfate | 222 | $30,770 | $139 |
| Lyrica | 42 | $22,460 | $535 |
| Leflunomide | 85 | $19,577 | $230 |
| Rasuvo | 26 | $15,641 | $602 |
| Methotrexate | 173 | $6,890 | $40 |
| Cevimeline | 22 | $4,517 | $205 |
| Celecoxib | 58 | $4,201 | $72 |
| Norco | 11 | $3,416 | $311 |
| Prednisone | 242 | $2,714 | $11 |
| Sulfasalazine | 69 | $2,473 | $36 |
| Mycophenolate Mofetil | 11 | $2,278 | $207 |
| Gabapentin | 120 | $1,759 | $15 |
| Duloxetine | 49 | $1,650 | $34 |
| Hydrocodone-Acetaminophen | 46 | $1,210 | $26 |
| Leucovorin | 27 | $826 | $31 |
| Omeprazole | 35 | $799 | $23 |
| Tramadol | 77 | $715 | $9 |
| Alendronate | 52 | $715 | $14 |
| Eszopiclone | 15 | $675 | $45 |
| Amitriptyline | 15 | $574 | $38 |
| Nifedipine Er | 13 | $563 | $43 |
| Methotrexate | 35 | $531 | $15 |
| Nabumetone | 24 | $443 | $18 |
| Allopurinol | 32 | $363 | $11 |
| Meloxicam | 36 | $348 | $10 |
| Diclofenac | 12 | $341 | $28 |
| Azathioprine | 11 | $334 | $30 |
| Acetaminophen-Codeine | 28 | $180 | $6 |
| Zolpidem | 18 | $104 | $6 |
2018: 34 drugs
| Cosentyx | 17 | $96,072 | $5,651 |
| Xeljanz | 20 | $79,404 | $3,970 |
| Enbrel Sureclick | 12 | $57,211 | $4,768 |
| Otezla | 15 | $50,213 | $3,348 |
| Hydroxychloroquine Sulfate | 211 | $36,374 | $172 |
| Lyrica | 58 | $32,464 | $560 |
| Leflunomide | 79 | $19,935 | $252 |
| Uloric | 21 | $12,758 | $608 |
| Methotrexate | 160 | $8,759 | $55 |
| Rasuvo | 14 | $7,053 | $504 |
| Celecoxib | 50 | $4,701 | $94 |
| Lidocaine | 14 | $3,163 | $226 |
| Sulfasalazine | 55 | $1,843 | $34 |
| Cevimeline | 16 | $1,705 | $107 |
| Prednisone | 172 | $1,603 | $9 |
| Duloxetine | 44 | $1,582 | $36 |
| Raloxifene | 12 | $1,543 | $129 |
| Mycophenolate Mofetil | 13 | $1,488 | $114 |
| Gabapentin | 73 | $1,246 | $17 |
| Hydrocodone-Acetaminophen | 33 | $925 | $28 |
| Nifedipine Er | 18 | $903 | $50 |
| Azathioprine | 16 | $760 | $47 |
| Leucovorin | 30 | $737 | $25 |
| Omeprazole | 43 | $713 | $17 |
| Nabumetone | 37 | $609 | $16 |
| Tramadol | 58 | $498 | $9 |
| Eszopiclone | 20 | $488 | $24 |
| Alendronate | 47 | $449 | $10 |
| Diclofenac | 11 | $355 | $32 |
| Methotrexate | 23 | $345 | $15 |
| Meloxicam | 25 | $231 | $9 |
| Allopurinol | 22 | $226 | $10 |
| Acetaminophen-Codeine | 15 | $110 | $7 |
| Zolpidem | 12 | $98 | $8 |
2017: 38 drugs
| Humira | 15 | $123,192 | $8,213 |
| Enbrel Sureclick | 23 | $99,845 | $4,341 |
| Enbrel | 11 | $98,865 | $8,988 |
| Forteo | 23 | $67,218 | $2,923 |
| Otezla | 20 | $59,534 | $2,977 |
| Hydroxychloroquine Sulfate | 318 | $59,198 | $186 |
| Humira | 12 | $53,952 | $4,496 |
| Lyrica | 59 | $30,159 | $511 |
| Leflunomide | 108 | $22,916 | $212 |
| Methotrexate | 235 | $18,057 | $77 |
| Uloric | 22 | $11,874 | $540 |
| Celecoxib | 78 | $7,022 | $90 |
| Rasuvo | 12 | $5,602 | $467 |
| Lidocaine | 18 | $3,617 | $201 |
| Sulfasalazine | 91 | $2,947 | $32 |
| Prednisone | 236 | $2,371 | $10 |
| Cevimeline | 15 | $1,852 | $123 |
| Mycophenolate Mofetil | 18 | $1,831 | $102 |
| Raloxifene | 12 | $1,735 | $145 |
| Duloxetine | 49 | $1,599 | $33 |
| Leucovorin | 62 | $1,341 | $22 |
| Eszopiclone | 24 | $859 | $36 |
| Gabapentin | 74 | $800 | $11 |
| Azathioprine | 18 | $778 | $43 |
| Alendronate | 66 | $679 | $10 |
| Nabumetone | 45 | $632 | $14 |
| Diclofenac | 24 | $626 | $26 |
| Allopurinol | 37 | $545 | $15 |
| Tramadol | 69 | $532 | $8 |
| Methotrexate | 29 | $532 | $18 |
| Nifedipine Er | 24 | $526 | $22 |
| Atovaquone-Proguanil | 12 | $492 | $41 |
| Hydrocodone-Acetaminophen | 43 | $439 | $10 |
| Omeprazole | 22 | $360 | $16 |
| Amitriptyline | 11 | $189 | $17 |
| Meloxicam | 33 | $179 | $5 |
| Zolpidem | 14 | $117 | $8 |
| Amlodipine Besylate | 17 | $106 | $6 |
2016: 26 drugs
| Enbrel | 14 | $61,105 | $4,365 |
| Hydroxychloroquine Sulfate | 292 | $47,413 | $162 |
| Methotrexate | 224 | $15,507 | $69 |
| Leflunomide | 88 | $15,200 | $173 |
| Lyrica | 29 | $11,621 | $401 |
| Uloric | 23 | $10,948 | $476 |
| Celecoxib | 52 | $4,646 | $89 |
| Prednisone | 255 | $2,595 | $10 |
| Sulfasalazine | 79 | $2,259 | $29 |
| Mycophenolate Mofetil | 24 | $2,092 | $87 |
| Duloxetine | 41 | $1,487 | $36 |
| Hydrocodone-Acetaminophen | 40 | $972 | $24 |
| Leucovorin | 41 | $811 | $20 |
| Oxycodone-Acetaminophen | 12 | $736 | $61 |
| Alendronate | 95 | $620 | $7 |
| Tramadol | 58 | $619 | $11 |
| Gabapentin | 68 | $593 | $9 |
| Nabumetone | 26 | $560 | $22 |
| Allopurinol | 27 | $549 | $20 |
| Eszopiclone | 14 | $506 | $36 |
| Meloxicam | 69 | $404 | $6 |
| Methotrexate | 32 | $389 | $12 |
| Zolpidem | 18 | $212 | $12 |
| Nifedical Xl | 11 | $169 | $15 |
| Cyclobenzaprine | 11 | $43 | $4 |
| Nifedipine Er | 12 | $40 | $3 |
2015: 21 drugs
| Hydroxychloroquine Sulfate | 277 | $41,240 | $149 |
| Methotrexate | 188 | $18,138 | $96 |
| Uloric | 13 | $8,402 | $646 |
| Leflunomide | 62 | $8,286 | $134 |
| Lyrica | 25 | $5,529 | $221 |
| Celecoxib | 22 | $3,135 | $143 |
| Prednisone | 251 | $2,420 | $10 |
| Mycophenolate Mofetil | 19 | $2,390 | $126 |
| Duloxetine | 27 | $2,131 | $79 |
| Sulfasalazine | 68 | $1,849 | $27 |
| Oxycodone-Acetaminophen | 12 | $890 | $74 |
| Eszopiclone | 12 | $737 | $61 |
| Gabapentin | 78 | $703 | $9 |
| Nabumetone | 25 | $652 | $26 |
| Alendronate | 88 | $646 | $7 |
| Hydrocodone-Acetaminophen | 30 | $539 | $18 |
| Allopurinol | 34 | $482 | $14 |
| Nifedipine Er | 13 | $339 | $26 |
| Tramadol | 34 | $258 | $8 |
| Meloxicam | 47 | $202 | $4 |
| Methotrexate | 12 | $187 | $16 |
2014: 21 drugs
| Forteo | 16 | $25,222 | $1,576 |
| Methotrexate | 114 | $11,284 | $99 |
| Duloxetine | 36 | $9,465 | $263 |
| Uloric | 16 | $6,890 | $431 |
| Hydroxychloroquine Sulfate | 239 | $6,489 | $27 |
| Leflunomide | 82 | $4,194 | $51 |
| Evoxac | 11 | $3,887 | $353 |
| Lyrica | 26 | $3,478 | $134 |
| Prednisone | 244 | $2,523 | $10 |
| Mycophenolate Mofetil | 17 | $2,103 | $124 |
| Lidocaine | 11 | $1,518 | $138 |
| Sulfasalazine | 56 | $1,160 | $21 |
| Hydrocodone-Acetaminophen | 30 | $742 | $25 |
| Alendronate | 78 | $718 | $9 |
| Nabumetone | 29 | $676 | $23 |
| Gabapentin | 26 | $560 | $22 |
| Allopurinol | 57 | $430 | $8 |
| Nifedipine Er | 14 | $317 | $23 |
| Meloxicam | 45 | $285 | $6 |
| Sulfazine | 11 | $245 | $22 |
| Tramadol | 12 | $177 | $15 |
2013: 22 drugs
| Forteo | 24 | $38,031 | $1,585 |
| Methotrexate | 115 | $9,770 | $85 |
| Uloric | 23 | $6,881 | $299 |
| Leflunomide | 83 | $6,057 | $73 |
| Cymbalta | 14 | $4,628 | $331 |
| Hydroxychloroquine Sulfate | 186 | $3,929 | $21 |
| Colcrys | 24 | $3,717 | $155 |
| Lunesta | 12 | $2,970 | $248 |
| Lyrica | 20 | $2,141 | $107 |
| Prednisone | 248 | $1,985 | $8 |
| Savella | 12 | $1,897 | $158 |
| Mycophenolate Mofetil | 12 | $1,598 | $133 |
| Alendronate | 120 | $1,018 | $8 |
| Nabumetone | 24 | $820 | $34 |
| Gabapentin | 40 | $788 | $20 |
| Hydrocodone-Acetaminophen | 49 | $756 | $15 |
| Sulfasalazine | 32 | $710 | $22 |
| Pantoprazole | 13 | $506 | $39 |
| Allopurinol | 69 | $395 | $6 |
| Nifedipine Er | 13 | $292 | $22 |
| Meloxicam | 30 | $225 | $8 |
| Amitriptyline | 12 | $40 | $3 |
Professional record
- NPI
- 1508956475
- Licence
- CA A84629California A84629: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 50 E Hamilton Ave Ste 200, Campbell, CA, 95008
- NPI first listed
- 2006-10-13
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1835 Park Ave, San Jose, CA, 95126